Clinical, Biochemical and Genetic Characteristics of MOGS-CDG: a Rare Congenital Disorder of Glycosylation

Purpose: To summarise the clinical, molecular and biochemical phenotype of mannosyl-oligosaccharide glucosidase-related congenital disorders of glycosylation (MOGS-CDG), which presents with variable clinical manifestations, and to analyse which clinical biochemical assay consistently supports diagnosis in individuals with bi-allelic variants in .

Methods: Phenotypic characterisation was performed through an international and multicentre collaboration. Genetic testing was done by exome sequencing and targeted arrays. Biochemical assays on serum and urine were performed to delineate the biochemical signature of MOGS-CDG.

Results: Clinical phenotyping revealed heterogeneity in MOGS-CDG, including neurological, immunological and skeletal phenotypes. Bi-allelic variants in were identified in 12 individuals from 11 families. The severity in each organ system was variable, without definite genotype correlation. Urine oligosaccharide analysis was consistently abnormal for all affected probands, whereas other biochemical analyses such as serum transferrin analysis was not consistently abnormal.

Conclusion: The clinical phenotype of MOGS-CDG includes multisystemic involvement with variable severity. Molecular analysis, combined with biochemical testing, is important for diagnosis. In MOGS-CDG, urine oligosaccharide analysis via matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry can be used as a reliable biochemical test for screening and confirmation of disease.

Citing Articles

Mass Spectrometry as a First-Line Diagnostic Aid for Congenital Disorders of Glycosylation.

Wada Y Mass Spectrom (Tokyo). 2025; 14(1):A0169.

PMID: 39931184 PMC: 11808201. DOI: 10.5702/massspectrometry.A0169.

Recruitment of USP10 by GCS1 to deubiquitinate GRP78 promotes the progression of colorectal cancer via alleviating endoplasmic reticulum stress.

Chen Y, Shen H, Wang Z, Huang C, Zhang H, Shao Y J Exp Clin Cancer Res. 2024; 43(1):261.

PMID: 39267084 PMC: 11396530. DOI: 10.1186/s13046-024-03176-8.

References

Hommes F, Varghese M . High-performance liquid chromatography of urinary oligosaccharides in the diagnosis of glycoprotein degradation disorders. Clin Chim Acta. 1991; 203(2-3):211-24. DOI: 10.1016/0009-8981(91)90293-l. View

Bammens R, Mehta N, Race V, Foulquier F, Jaeken J, Tiemeyer M . Abnormal cartilage development and altered N-glycosylation in Tmem165-deficient zebrafish mirrors the phenotypes associated with TMEM165-CDG. Glycobiology. 2015; 25(6):669-82. PMC: 4410832. DOI: 10.1093/glycob/cwv009. View

Ota M, Miyahara J, Itano A, Sugiura H, Ohki S . Mannosyl-oligosaccharide glucosidase - congenital disorder of glycosylation: A patient with novel variants. Pediatr Int. 2020; 62(3):417-418. DOI: 10.1111/ped.14110. View

Dickinson M, Flenniken A, Ji X, Teboul L, Wong M, White J . High-throughput discovery of novel developmental phenotypes. Nature. 2016; 537(7621):508-514. PMC: 5295821. DOI: 10.1038/nature19356. View

Monto A . Viral respiratory infections in the community: epidemiology, agents, and interventions. Am J Med. 1995; 99(6B):24S-27S. PMC: 7172478. DOI: 10.1016/s0002-9343(99)80307-6. View

Anzai R, Tsuji M, Yamashita S, Wada Y, Okamoto N, Saitsu H . Congenital disorders of glycosylation type IIb with MOGS mutations cause early infantile epileptic encephalopathy, dysmorphic features, and hepatic dysfunction. Brain Dev. 2020; 43(3):402-410. DOI: 10.1016/j.braindev.2020.10.013. View

Ng B, Freeze H . Perspectives on Glycosylation and Its Congenital Disorders. Trends Genet. 2018; 34(6):466-476. PMC: 5959770. DOI: 10.1016/j.tig.2018.03.002. View

Bieberich E . Synthesis, Processing, and Function of N-glycans in N-glycoproteins. Adv Neurobiol. 2014; 9:47-70. PMC: 4236024. DOI: 10.1007/978-1-4939-1154-7_3. View

Bosch D, Boonstra F, de Leeuw N, Pfundt R, Nillesen W, de Ligt J . Novel genetic causes for cerebral visual impairment. Eur J Hum Genet. 2015; 24(5):660-5. PMC: 4930090. DOI: 10.1038/ejhg.2015.186. View

10.

Schenk B, Imbach T, Frank C, Grubenmann C, Raymond G, Hurvitz H . MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest. 2001; 108(11):1687-95. PMC: 200989. DOI: 10.1172/JCI13419. View

11.

Gruber C, Keil T, Kulig M, Roll S, Wahn U, Wahn V . History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008; 19(6):505-12. DOI: 10.1111/j.1399-3038.2007.00688.x. View

12.

Li W, Han C, Liu C, Xing H, Ding D . ANGPTL2 deletion inhibits osteoclast generation by modulating NF-κB/MAPKs/Cyclin pathways. Biochem Biophys Res Commun. 2018; 503(3):1471-1477. DOI: 10.1016/j.bbrc.2018.07.065. View

13.

Coman D, Irving M, Kannu P, Jaeken J, Savarirayan R . The skeletal manifestations of the congenital disorders of glycosylation. Clin Genet. 2008; 73(6):507-15. DOI: 10.1111/j.1399-0004.2008.01015.x. View

14.

Burgess R, Wang S, McTague A, Boysen K, Yang X, Zeng Q . The Genetic Landscape of Epilepsy of Infancy with Migrating Focal Seizures. Ann Neurol. 2019; 86(6):821-831. PMC: 7423163. DOI: 10.1002/ana.25619. View

15.

Chang I, He M, Lam C . Congenital disorders of glycosylation. Ann Transl Med. 2019; 6(24):477. PMC: 6331365. DOI: 10.21037/atm.2018.10.45. View

16.

Kim Y, Seo G, Jung E, Jang J, Kim S, Lee B . Characteristic dysmorphic features in congenital disorders of glycosylation type IIb. J Hum Genet. 2017; 63(3):383-386. DOI: 10.1038/s10038-017-0386-7. View

17.

Lesnik Oberstein S, Kriek M, White S, Kalf M, Szuhai K, den Dunnen J . Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase. Am J Hum Genet. 2006; 79(3):562-6. PMC: 1559553. DOI: 10.1086/507567. View

18.

Zhao P, Peng X, Luo S, Huang Y, Tan L, Shao J . Identification and characterization of novel mutations in MOGS in a Chinese patient with infantile spams. Neurogenetics. 2020; 21(2):97-104. DOI: 10.1007/s10048-019-00590-5. View

19.

Cai G, Salonikidis P, Fei J, Schwarz W, Schulein R, Reutter W . The role of N-glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal N-glycans facilitate efficient GABA-uptake activity of the GABA transporter. FEBS J. 2005; 272(7):1625-38. DOI: 10.1111/j.1742-4658.2005.04595.x. View

20.

Qin C, Baba O, Butler W . Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med. 2004; 15(3):126-36. DOI: 10.1177/154411130401500302. View